← Back to Search

Teleophthalmology for Diabetic Retinopathy

N/A

Waitlist Available

Led By Yao Liu, MD, MS

Research Sponsored by University of Wisconsin, Madison

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 12 months, 36 months, 48 months

Awards & highlights

No Placebo-Only Group

Summary

This trial tests if an implementation program can increase diabetic eye screening rates using teleophthalmology in rural health systems, with 10 systems and 10,000 patients taking part.

Who is the study for?

This trial is for rural health systems that already have a teleophthalmology program for diabetic eye screening but with less than 50% screening rates. These systems must serve patients in areas defined as rural and agree to share de-identified patient data.

What is being tested?

The I-SITE program aims to improve diabetic eye screening rates using teleophthalmology in rural health settings. The study will involve up to 10,000 patients and 100 clinical staff across multiple sites over a period of up to 48 months.

What are the potential side effects?

Since this trial focuses on the implementation of a service (teleophthalmology) rather than a medical treatment, traditional side effects are not applicable. However, there may be technical issues or challenges in data management.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 12 months, 36 months, 48 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 12 months, 36 months, 48 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 12 months, 36 months, 48 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Proportion of Patients Who Complete Annual Diabetic Eye Screening

Secondary study objectives

Change in Proportion of Patients Who Complete Annual Diabetic Eye Screening

Eye

Identification of workflow strategies, organizational factors, and implementation components that distinguish between health systems with high and low teleophthalmology use

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: InterventionExperimental Treatment1 Intervention

Up to 10 rural health systems will be participating in I-SITE implementation with cluster-randomization of the order of initiation for the intervention. All sites will receive usual care teleophthalmology prior to I-SITE implementation.

Do I qualify?Apply below to find out